On May 21-22 the Inno4Vac interim technical review successfully virtually took place. During these two days sub-topic and work package leads, EFPIA representatives, members of the Coordination and Scientific Management Team (CSMT) and members of the Steering Committee presented scientific, technological, and other aspects relating to the project execution over the past 2.5 years.
External experts assessed the work carried out under the project reviewing such aspects as:
The continued relevance of the objectives and breakthrough potential with respect to the scientific and industrial state of the art,
Expected potential impact in scientific, technological, economic, competitive and social terms,
Sustainability plan to ensure the exploitation of the project results after the end of the project and Innovation Radar to identify high-potential innovations.
Moreover, Q&A and feedback sessions occurred during the interim review, and recommendations to the whole consortium and IMI JU Executive Office will be consolidated in a written report.
The Inno4Vac consortium thanks the IHI project officer Manuel de la Guia Solaz and the external expert panel.
Contact:
Dr. Irina Meln (Project and Innovation Manager at the European Vaccine Initiative)
Email: irina.meln@euvaccine.eu
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007799 (Inno4Vac). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (www.imi.europa.eu). This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Comments